Herasimtschuk AA - Search Results

1

Changes in T Cell and Dendritic Cell Phenotype from Mid to Late Pregnancy Are Indicative of a Shift from Immune Tolerance to Immune Activation.

Shah NM, Herasimtschuk AA, Boasso A, Benlahrech A, Fuchs D, Imami N, Johnson MR. Shah NM, et al. Among authors: herasimtschuk aa. Front Immunol. 2017 Sep 15;8:1138. doi: 10.3389/fimmu.2017.01138. eCollection 2017. Front Immunol. 2017. PMID: 28966619 Free PMC article.

2

Dysregulated immunophenotypic attributes of plasmacytoid but not myeloid dendritic cells in HIV-1 infected individuals in the absence of highly active anti-retroviral therapy.

Benlahrech A, Yasmin A, Westrop SJ, Coleman A, Herasimtschuk A, Page E, Kelleher P, Gotch F, Imami N, Patterson S. Benlahrech A, et al. Clin Exp Immunol. 2012 Nov;170(2):212-21. doi: 10.1111/j.1365-2249.2012.04647.x. Clin Exp Immunol. 2012. PMID: 23039892 Free PMC article.

3

Long-Term Non-Progression and Broad HIV-1-Specific Proliferative T-Cell Responses.

Imami N, Westrop SJ, Grageda N, Herasimtschuk AA. Imami N, et al. Among authors: herasimtschuk aa. Front Immunol. 2013 Mar 1;4:58. doi: 10.3389/fimmu.2013.00058. eCollection 2013. Front Immunol. 2013. PMID: 23459797 Free PMC article.

4

Low-dose growth hormone for 40 weeks induces HIV-1-specific T cell responses in patients on effective combination anti-retroviral therapy.

Herasimtschuk AA, Hansen BR, Langkilde A, Moyle GJ, Andersen O, Imami N. Herasimtschuk AA, et al. Clin Exp Immunol. 2013 Sep;173(3):444-53. doi: 10.1111/cei.12141. Clin Exp Immunol. 2013. PMID: 23701177 Free PMC article. Clinical Trial.

5

Multifarious immunotherapeutic approaches to cure HIV-1 infection.

Imami N, Herasimtschuk AA. Imami N, et al. Among authors: herasimtschuk aa. Hum Vaccin Immunother. 2015;11(9):2287-93. doi: 10.1080/21645515.2015.1021523. Hum Vaccin Immunother. 2015. PMID: 26048144 Free PMC article. Clinical Trial.

6

Short Communication: Therapeutic Immunization Benefits Mucosal-Associated Invariant T Cell Recovery in Contrast to Interleukin-2, Granulocyte-Macrophage Colony-Stimulating Factor, and Recombinant Human Growth Hormone Addition in HIV-1+ Treated Patients: Individual Case Reports from Phase I Trial.

Cocker ATH, Greathead L, Herasimtschuk AA, Mandalia S, Kelleher P, Imami N. Cocker ATH, et al. Among authors: herasimtschuk aa. AIDS Res Hum Retroviruses. 2019 Mar;35(3):306-309. doi: 10.1089/AID.2018.0176. Epub 2019 Feb 5. AIDS Res Hum Retroviruses. 2019. PMID: 30600702 Free article. Clinical Trial.

7

Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infection.

Herasimtschuk A, Downey J, Nelson M, Moyle G, Mandalia S, Sikut R, Adojaan M, Stanescu I, Gotch F, Imami N. Herasimtschuk A, et al. Vaccine. 2014 Dec 5;32(51):7005-7013. doi: 10.1016/j.vaccine.2014.09.072. Epub 2014 Oct 22. Vaccine. 2014. PMID: 25454870 Free article. Clinical Trial.

8

Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up.

Herasimtschuk AA, Westrop SJ, Moyle GJ, Downey JS, Imami N. Herasimtschuk AA, et al. J Immune Based Ther Vaccines. 2008 Oct 31;6:7. doi: 10.1186/1476-8518-6-7. J Immune Based Ther Vaccines. 2008. PMID: 18976455 Free PMC article.

9

The retrocyclin analogue RC-101 prevents human immunodeficiency virus type 1 infection of a model human cervicovaginal tissue construct.

Cole AL, Herasimtschuk A, Gupta P, Waring AJ, Lehrer RI, Cole AM. Cole AL, et al. Immunology. 2007 May;121(1):140-5. doi: 10.1111/j.1365-2567.2006.02553.x. Epub 2007 Jan 23. Immunology. 2007. PMID: 17250585 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

9 results

Search Page